Major life-sciences push tied to state visits
GlaxoSmithKline said it will invest $30 billion in U.S. research, development and manufacturing over five years, including a new Pennsylvania factory for cancer and respiratory drugs. The package was announced alongside high-level diplomatic visits highlighting industrial ties.
Jobs and supply-chain goals highlighted
GSK said the investment will boost domestic drug production and create thousands of jobs while strengthening transatlantic R&D links. Analysts said the move signals renewed focus on onshore manufacturing for strategic medicines.